人福医药
(600079)
| 流通市值：287.65亿 | | | 总市值：304.25亿 |
| 流通股本：15.43亿 | | | 总股本：16.32亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 17,883,352,478.34 | 12,063,918,105.77 | 6,137,399,886.05 | 25,435,484,349.43 |
| 营业收入 | 17,883,352,478.34 | 12,063,918,105.77 | 6,137,399,886.05 | 25,435,484,349.43 |
| 二、营业总成本 | 15,280,234,823.45 | 10,297,053,275.11 | 5,336,905,257.79 | 22,665,868,260.22 |
| 营业成本 | 9,308,721,665.01 | 6,251,175,501.23 | 3,157,243,979.93 | 14,103,261,109.49 |
| 税金及附加 | 172,452,543.6 | 115,831,291.24 | 53,801,601.16 | 178,308,916.4 |
| 销售费用 | 3,291,340,743.67 | 2,213,285,627.7 | 1,164,947,366.72 | 4,630,565,520.92 |
| 管理费用 | 1,244,701,195.57 | 852,536,007.81 | 485,191,248.81 | 1,932,469,488.11 |
| 研发费用 | 1,050,412,027.47 | 743,381,611.67 | 408,787,039.15 | 1,470,559,384.57 |
| 财务费用 | 212,606,648.13 | 120,843,235.46 | 66,934,022.02 | 350,703,840.73 |
| 其中:利息费用 | 214,482,340.03 | 154,942,335.49 | 80,918,552.85 | 351,369,188.89 |
| 其中:利息收入 | 17,397,099.46 | 20,721,088.64 | 9,086,599.35 | 52,098,439.42 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,041,835.76 | -1,618,385.31 | -847,377.55 | 112,716,765.01 |
| 加:投资收益 | 59,393,469.54 | 47,365,964.55 | 26,513,827.18 | 133,085,667.02 |
| 资产处置收益 | -512,831.49 | -351,249.07 | 1,840,394.68 | -4,472,024.18 |
| 资产减值损失(新) | -18,193,699.16 | -18,073,491.14 | 1,330,010.64 | -393,861,278.28 |
| 信用减值损失(新) | -44,695,015.18 | -34,487,669.13 | -15,983,130.09 | -283,184,107.26 |
| 其他收益 | 102,709,282.93 | 74,813,498.51 | 43,955,625.3 | 188,127,460.48 |
| 四、营业利润 | 2,698,777,025.77 | 1,834,513,499.07 | 857,303,978.42 | 2,522,028,572 |
| 加:营业外收入 | 4,786,663.92 | 3,941,102.77 | 1,331,732.81 | 9,364,111.05 |
| 减:营业外支出 | 71,903,073.42 | 49,229,068.94 | 31,193,035.99 | 108,562,341.6 |
| 五、利润总额 | 2,631,660,616.27 | 1,789,225,532.9 | 827,442,675.24 | 2,422,830,341.45 |
| 减:所得税费用 | 448,538,922.8 | 292,051,530.39 | 128,827,632.17 | 644,487,411.01 |
| 六、净利润 | 2,183,121,693.47 | 1,497,174,002.51 | 698,615,043.07 | 1,778,342,930.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,183,121,693.47 | 1,497,174,002.51 | 698,615,043.07 | 1,778,342,930.44 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,688,576,505.5 | 1,154,666,721.67 | 540,345,459.39 | 1,329,744,984.33 |
| 少数股东损益 | 494,545,187.97 | 342,507,280.84 | 158,269,583.68 | 448,597,946.11 |
| 扣除非经常损益后的净利润 | 1,665,647,702.63 | 1,130,463,756.71 | 530,969,947.35 | 1,138,885,517.83 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.03 | 0.71 | 0.33 | 0.82 |
| (二)稀释每股收益 | 1.03 | 0.71 | 0.33 | 0.82 |
| 八、其他综合收益 | 130,814,456.62 | 87,566,822.09 | -26,945,270.08 | 132,562,352.95 |
| 归属于母公司股东的其他综合收益 | 122,891,817.28 | 78,871,522.18 | -29,588,767.26 | 148,435,495.43 |
| 九、综合收益总额 | 2,313,936,150.09 | 1,584,740,824.6 | 671,669,772.99 | 1,910,905,283.39 |
| 归属于母公司股东的综合收益总额 | 1,811,468,322.78 | 1,233,538,243.85 | 510,756,692.13 | 1,478,180,479.76 |
| 归属于少数股东的综合收益总额 | 502,467,827.31 | 351,202,580.75 | 160,913,080.86 | 432,724,803.63 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |